2Stein E Results of phase Ⅰ /Ⅱ clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor[J].Eur Heart J Supplements, 2001, 31( 1): 11.
3Bays HE, Moore PB, Orehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase Ⅱ studies[J].Clin Ther, 2001, 23( 5): 1 029.
5Lamarche B, Tchemof A, Moorjani S, et al. Small dense LDL particle as a predictor of ischemic heart disease in men[J].Circulation, 1997, 95( 1): 96.
6Scandinavian Simvastatin Survival Study Group Rand- omised trial of cholesterol lowering in 4 444 patients with coronary heart disease; the Scandinavian Simvast- atin Survival Study 4S[J].Lancet, 1994, 344( 6): 1 383.
7Battula SB, De Backer G, Faergeman O, et al. Postpra- ndial apolipoprotein B48 and B100- containing lipopro- on teins in type 2 diabetes: do stains have a specific effect on triglyceride metabolism[J].Metabolism, 2000, 49( 5): 1 049.
8West of Scotland coronary prevention study group Inf- luence of pravastatin and plasma levels on clinical even- ts in the Scotland coronary prevention study( Woscops)[J]Circulation, 1998, 97( 11): 1 440.
9Downs JR, Clearfield M, Weis S, et al. Primary preven- tion of acute coronary events with lovastatin in men and women with average cholesterol levels: result of AFCAPS/TexCaps[J].JAMA, 1998, 279( 7): 1 615.
10Noji Y, Higashikata T, Inazu A, et al. Long- term treatment with pitavastatin( NK- 104), a new HMG- CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia[J].Atherosclerosis, 2002, 163( 1): 157.
